Fengwei Wang
Overview
Explore the profile of Fengwei Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin J, Yin Y, Cao J, Zou B, Han K, Chen Y, et al.
Adv Sci (Weinh)
. 2025 Feb;
:e2410058.
PMID: 39921866
Metabolic dysregulation has been implicated as a key factor in colorectal cancer (CRC) initiation, however, the underlying driving forces and mechanisms remain poorly understood. Herein, transcriptome profiling of paired early-stage...
2.
Liu H, Nie X, Wang F, Chen D, Zeng Z, Shu P, et al.
Front Aging Neurosci
. 2024 Dec;
16:1450337.
PMID: 39713269
Background: It is been noted that the expression levels of numerous genes undergo changes as individuals age, and aging stands as a primary factor contributing to age-related diseases. Nevertheless, it...
3.
Liu Y, Bai X, Wang H, Wang J, Li S, Zhang H, et al.
Biochem Biophys Res Commun
. 2024 Dec;
742:151155.
PMID: 39662453
Photothermal therapy (PTT) is an innovative cancer treatment that leverages heat generated from near-infrared light exposure to induce tumor cell death. A major challenge in PTT is achieving precise delivery...
4.
Long Z, Lu Y, Li M, Li J, Chen G, Wang F, et al.
Cancer Med
. 2024 Dec;
13(23):e70416.
PMID: 39618078
Background: The aim of this study was to analyze the potential therapeutic targets of anlotinib using the patient-derived xenografts (PDX) and evaluate the efficacy of the combination of chemotherapy and...
5.
Wang X, Ding Y, Li S, Wang F, Yang L, Zhang H, et al.
Int J Pharm
. 2024 Nov;
669():125003.
PMID: 39603436
Immunotoxin has become a highly promising therapy for treating cancer and has achieved good results in preclinical trials targeting various cancers. However, there are still some issues that limit the...
6.
Zhang L, Zheng C, Sun Z, Wang H, Wang F
Oncol Lett
. 2024 Nov;
29(1):14.
PMID: 39526301
[This retracts the article DOI: 10.3892/ol.2019.10737.].
7.
Jin X, Lv Y, Bie F, Duan J, Ma C, Dai M, et al.
Cell Death Differ
. 2024 Oct;
32(3):466-479.
PMID: 39472692
Oxaliplatin-based therapeutics is a widely used treatment approach for hepatocellular carcinoma (HCC) patients; however, drug resistance poses a significant clinical challenge. Epigenetic modifications have been implicated in the development of...
8.
Zheng W, Li S, Shi Z, Su K, Ding Y, Zhang L, et al.
J Nanobiotechnology
. 2024 Sep;
22(1):562.
PMID: 39272180
Background: Tumor neoantigen peptide-based vaccines, systemic immunotherapies that enhance antitumor immunity by activating and expanding antigen-specific T cells, have achieved remarkable results in the treatment of a variety of solid...
9.
Qiu X, Wang F, Zhang Q, Tao G, Zhou S
Sci Rep
. 2024 Aug;
14(1):19268.
PMID: 39164405
Due to various unavoidable reasons or gross error elimination, missing data inevitably exist in global navigation satellite system (GNSS) position time series, which may result in many analysis methods not...
10.
Lin J, Zou B, Li H, Wang J, Li S, Cao J, et al.
Cell Signal
. 2024 May;
120:111234.
PMID: 38795810
Tumor dormancy is the underpinning for cancer relapse and chemoresistance, leading to massive cancer-related death in colorectal cancer (CRC). However, our comprehension of the mechanisms dictating tumor dormancy and strategies...